12/17/2025
We’re excited to share a major milestone at Penn Medicine Doylestown Health that is expanding our treatment options for patients with atrial fibrillation (AFib), a common heart condition that causes the heart’s upper chambers to beat irregularly, often too fast.
An advanced system recently approved by the FDA allows doctors to locate the source of the problem, destroy the tissue causing the irregular heartbeat, and confirm the success of the procedure, all with a single device. What’s even more exciting? In clinical trials, patients reported significant improvements in their overall well-being, both mentally and physically.
Known as pulse field ablation, this technology “has unique safety advantages over the typical thermal methods because it can more selectively target cardiac tissue while avoiding damage to adjacent tissue,” said Dr. Robert M. Sangrigoli, director of the Electrophysiology Lab at Doylestown Health.
“Our heart and vascular team has always been committed to identifying ways to improve and accelerate our ability to treat patients, and this is bringing better care to patients suffering from AFib.”
With more than 20 years of experience, Dr. Sangrigoli is a leading expert in heart rhythm disorders and has been a driving force behind the Electrophysiology Program at Doylestown Hospital since its inception in 2001. His skill in advanced treatments, including radiofrequency ablation, cryoablation, and pulsed field ablation, has helped countless patients. Through his involvement in clinical trials, he helps ensure patients have access to the latest, most effective therapies available.
This technology is just one example of how Doylestown Health continues to lead the way in the fight against heart disease and improve the lives of those we serve.